ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021
Distinct diarrhea profiles during outpatient chemotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra.Scientific reports · 2022Trial
- Patterns of self-reported diarrhea in patients with cancer receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Impact of Multimorbidity on Symptom Burden and Symptom Clusters in Patients Receiving Chemotherapy.Cancer medicine · 2025Article
- Higher Lifetime Stress and Symptom Burden Contribute to the Occurrence of Shortness of Breath.Seminars in oncology nursing · 2023Article
- Distinct Shortness of Breath Profiles in Oncology Outpatients Undergoing Chemotherapy.Journal of pain and symptom management · 2023Article
- Cognitive appraisal of the disease and stress level in lung cancer patients. The mediating role of coping styles.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Experiences of breast cancer survivors during the COVID-19 pandemic: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Distinct dyadic coping profiles in Chinese couples with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeChemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50 to 80% of patients. Given that the majority of the data on the occurrence and severity of CID is based on physician-rated toxicity criteria, this study's purposes were to identify subgroups of patients with distinct CID profiles and determine how these subgroups differ in terms of demographic and clinical characteristics; severity, frequency, and distress of CID; the co-occurrence of common GI symptoms; and QOL.
methodsPatients (n = 1133) completed the Memorial Symptom Assessment Scale six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct diarrhea profiles. Differences among these subgroups were evaluated using parametric and nonparametric statistics.
resultsFour distinct diarrhea profiles were identified: none (58.3%), decreasing (22.0%), increasing (5.2%), and high (14.5%). Compared with the none class, patients in the high class had a lower functional status, a worse comorbidity profile, were more likely to have gastrointestinal cancer, and were more likely to receive chemotherapy on a 14-day cycle. No differences were found among the classes in the percentages of patients who received chemotherapy with a targeted therapy.
conclusionGiven that CID occurred in over 40% of the patients, clinicians should assess for this symptom and other common GI symptoms and initiate appropriate pharmacologic and dietary interventions.
Indexed as
Identifiers
32918132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.